This study has several important strengths: the prospective design provided more reliable findings; the inclusion of resistin as a biomarker has added a significant novel contribution to the stroke prognosis research; the patients were recruited exclusively during the COVID-19 pandemic, providing insights into the contemporary situation; and we conducted successful validation of the predictive model in an independent cohort. The gene discussed is RETN; the disease is Stroke.